GlassScriptPhysician profile
Stephen A Boudreaux
NPI 1649291238
$11,019.63
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,419 · 2020: $1,593 · 2021: $2,103 · 2022: $2,296 · 2023: $2,025 · 2024: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.35 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,726.06 | 2019-2024 | Farxiga, Breztri |
| Abbvie INC. | $1,234.15 | 2021-2024 | Vraylar, Viberzi, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $935.37 | 2019-2023 | Jardiance, Trijardy Xr |
| Lilly USA, LLC | $919.77 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $874.55 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $698.61 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $633.28 | 2019-2022 | |
| Amgen INC. | $612.99 | 2019-2024 | Evenity, Repatha, Otezla |
| Allergan, INC. | $395.37 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.78 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $390.13 | 2021-2023 | |
| Corium, LLC | $360.89 | 2022-2024 | Azstarys |
| Astellas Pharma US INC | $294.83 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $238.09 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $193.65 | 2019-2023 | Belsomra, Steglatro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $163.27 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $131.64 | 2019-2023 | |
| Abbott Laboratories | $102.81 | 2022-2024 | Freestyle Libre 3 |
| Eisai INC. | $92.11 | 2020-2021 | |
| Dexcom, INC. | $85.90 | 2021-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $84.35 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $70.45 | 2019-2022 | |
| Biogen, INC. | $70.43 | 2021-2024 | Skyclarys, Skyclarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.84 | 2019-2020 | |
| Sanofi Pasteur INC. | $53.27 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $33.15 | 2021-2022 | |
| Almatica Pharma LLC | $26.83 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $25.01 | 2023 | Prehevbrio |
| Shire North American Group INC | $24.75 | 2019 | |
| Currax Pharmaceuticals LLC | $24.19 | 2020-2022 | |
| Exact Sciences Corporation | $22.35 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $20.85 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $19.19 | 2022 | |
| Neos Therapeutics, LP | $15.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Boudreaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.